Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Abuse Liability of ADAIR vs Crushed D-Amphetamine in Recreational Users
NCT04232644Phase 1Completed
- Sponsor
- GRI Bio, Inc.
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of salmeterol + fluticasone in attention deficit hyperactivity disorder (ADHD) and narcolepsy (2 arms), sponsored by GRI Bio, Inc. Primary endpoints: Treatment-emergent adverse event reporting, Abnormal Vital Signs and 3 more. Started May 2019; status: completed.
02
Drugs
salmeterol + fluticasone
03
Conditions
attention deficit hyperactivity disorder (ADHD)narcolepsy
Beyond the preview
Go deeper on NCT04232644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232644.